

only taking clopidogrel. These findings will be presented this month at the annual meeting of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR).

Study details

The Clopidogrel Outcomes Study investigated medical and pharmacy claims data of 16,690 patients who were taking clopidogrel following a stent procedure and tracked the study subjects for a 12-month period from 2005 to 2006. The study compared a group of 6,828 patients who were concurrently taking a PPI and clopidogrel to a group of 9,862 patients who were only taking clopidogrel. When PPIs were examined individually all of the associations were highly statistically significant.

To address a related issue that has raised questions about the PPI/clopidogrel interaction, the researchers also looked at whether or not PPIs independently increase the risk of a CV event. The results of this study found that there was no independent effect from taking a PPI in the absence of clopidogrel. The study included 1,641 patients who had undergone a stent procedure but were not taking clopidogrel and compared CV event hospitalizations of patients on a PPI to those not taking a PPI. These findings were recently presented at the American Heart Association's Scientific Forum on Quality of Care and Outcomes Research in Cardiovascular and Stroke (QCOR).

“Our study, along with a 2007 FDA review and other researchers' work, provides strong evidence that PPIs do not independently raise cardiovascular risks for stent patients and further strengthens the observation that this interaction exists between PPIs and clopidogrel and impairs the effectiveness of the antiplatelet drug,” said Epstein. “Given the totality of the evidence generated on this interaction and the known benefits of clopidogrel in reducing the risk of death, heart attack and stroke after coronary stenting, patients and their physicians should continue to trust in the use of this medication and consider a PPI only when clearly indicated.”

About Medco

Medco Health Solutions, Inc (NYSE: MHS) is a leading health care company, serving the needs of more than 60 million people. *Medco, the world's most advanced pharmacy*®, provides clinically driven pharmacy services designed to improve the quality of care and lower total health care costs for private and public employers, health plans, labor unions and government agencies of all sizes, and for individuals served by Medicare Part D Prescription Drug Plans. Through its unique *Medco Therapeutic Resource Centers*® and the Accredo Health Group, Medco's Specialty Pharmacy, the company is creating innovative models for the care of patients with chronic and complex conditions. Medco is a leader in the emerging field of personalized medicine and in applying evidence-based protocols to elevate the practice of pharmacy – a key element in reforming America's health care system. Medco is ranked number 45 on the Fortune 500 list, with 2008 revenues of more than \$51 billion. For more information about Medco, go to <http://www.medcohealth.com>.

This press release contains “forward-looking statements” as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements involve risks and uncertainties that may cause results to differ materially from those set forth in the statements. No forward-looking statement can be guaranteed, and actual results may differ materially from those projected. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise. Forward-looking statements in this press release should be evaluated together with the risks and uncertainties that affect our business, particularly those mentioned in the Risk Factors section of the Company's Annual Report on Form 10-K and Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission.

###